Eliem Therapeutics Return on Investment 2021-2024 | CLYM
Current and historical return on investment (ROI) values for Eliem Therapeutics (CLYM) over the last 10 years.
| Eliem Therapeutics ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-06-30 |
$-0.07B |
|
inf% |
| 2024-03-31 |
$-0.02B |
|
inf% |
| 2023-12-31 |
$-0.04B |
|
inf% |
| 2023-09-30 |
$-0.05B |
|
inf% |
| 2023-06-30 |
$-0.05B |
|
inf% |
| 2023-03-31 |
$-0.06B |
|
inf% |
| 2022-12-31 |
$-0.05B |
|
inf% |
| 2022-09-30 |
$-0.05B |
|
inf% |
| 2022-06-30 |
$-0.05B |
|
inf% |
| 2022-03-31 |
$-0.04B |
|
inf% |
| 2021-12-31 |
$-0.04B |
|
inf% |
| 2021-06-30 |
$-0.02B |
|
inf% |
| 2021-03-31 |
$-0.01B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
